Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Condition: Pathologic Residual Cancer Cells Interventions: Drug: Capecitabine, Oral, 500 Mg; Drug: Vinorelbine Tartrate Oral Sponsor: Zhiyong Yu Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials